A 27-year-old female with a history of hypertension was diagnosed with pan-ulcerative
colitis (UC) after experiencing several weeks of diarrhea, hematochezia, and abdominal …

Methods: A commercial database (Explorys Inc, Cleveland, OH) was utilized, which included
electronic health record data from 26 major integrated US healthcare systems. We identified …

A 32-year-old female with no significant past medical history was diagnosed with ulcerative
proctitis in the setting of abdominal pain and hematochezia following a miscarriage. Index …

Background Data comparing vedolizumab (VDZ) and ustekinumab (UST) in patients with
ulcerative colitis (UC) previously treated with tumor necrosis factor inhibitor (TNFi) and …

BACKGROUND Therapies for ulcerative colitis include mesalamine, immunomodulators,
biologics, and small molecules. Unfortunately, patient response is not universal, and efficacy …

Background Vedolizumab is often used as the first-line advanced therapy for patients with
moderate to severe ulcerative colitis (UC). There is currently no data reporting the efficacy …

We read with interest the article by Noman et al., 1 reporting the long-term endoscopic and
histological efficacy of vedolizumab in patients with inflammatory bowel disease in an open …

To the Editors, Therapeutic management of inflammatory bowel disease (IBD) after liver
transplantation (LT) can be challenging because the patient is already immunosuppressed …

JLE - Hépato-Gastro & Oncologie Digestive - Treatment of ulcerative colitis in failure of a first
line of biotherapy JLE Home Bookstore Search for books Collections New books and E-books …

LINKED CONTENT This article is linked to Bokemeyer et al papers. To view these articles,
visit https://doi. org/10.1111/apt. 17616 and https://doi. org/10.1111/apt. 17770